SGH
RPRX icon

Sivik Global Healthcare’s Royalty Pharma RPRX Stock Holding History

Sivik Global Healthcare’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-45,008
Closed -$1.81M – 46
2022
Q3 		$1.81M Buy
+45,008
New +$1.92M 1% 36

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sivik Global Healthcare's RPRX Position: Q4 2022 in Review

Sivik Global Healthcare sold out of Royalty Pharma (RPRX) in Q4 2022, closing a stake of 45,008 shares — an estimated $1.81M sold.

Sivik Global Healthcare first reported a position in RPRX in Q3 2022 and held it in 1 quarter. The position peaked at $1.81M in Q3 2022. 336 funds tracked by Wall St. Rank hold RPRX as of Q4 2022.

  • Sivik Global Healthcare reported no remaining Royalty Pharma position as of Q4 2022 after selling out during the quarter.
  • Sivik Global Healthcare sold 45,008 Royalty Pharma shares in Q4 2022, an estimated $1.81M.
  • Sivik Global Healthcare first reported a position in Royalty Pharma in Q3 2022 and held it in 1 quarter.
  • Sivik Global Healthcare's Royalty Pharma position peaked at $1.81M in Q3 2022.
  • 336 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2022.

Based on Sivik Global Healthcare's 13F filing for Q4 2022, filed 8 Feb 2023.